leisure time -WSS

leisure time

author：knowledge 2025-10-01 00:47:01 - browse：76

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

hotspot

WSS

Elizabeth Holmes banned from government health programs

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Test for long Covid? Researchers find new clue in blood samples

Prior authorization will have to move faster under new Biden rule

Independent physicians launch a new lobbying group

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medicare details structure of new drug price negotiation program

Research misconduct: Proposed new rules face resistance

Anesthesiologist group: stop taking Ozempic before surgery

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

United colonoscopy coverage change 'may cost lives,' doctors say

Why failed clinical trials don’t always spell doom for a new drug

New air purifier tech could be key to improving indoor air quality

Research misconduct: Proposed new rules face resistance

Peter Hotez and the public health issue of online harassment

For Cytokinetics, FDA rejection of heart drug would help, not hinder

entertainment

FDA clears AI tool for detecting skin cancer

Francis Collins on trust in science and how Covid communications failed

New brain studies show LSD's effects on the brain in full color

New brain studies show LSD's effects on the brain in full color

Naloxone nonprofit donates 200,000 doses after FDA approval

Research misconduct: Proposed new rules face resistance

focus

hotspot

hotspot

explore